In a phase IIa study conducted by Bisonnette et al., the topical (ointment) form of tofacitinib, an inhibitor of JAK1, JAK2, and JAK3 (Figure 3b), demonstrated both safety and efficacy in treating mild-to-moderate AD. This evidence concerns the gene JAK2 and Alzheimer disease.